Hemispherx Biopharma, Inc. (NYSE Amex: HEB) reports a Q3 loss of $0.02, 1 cent better than estimates.

On ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE